Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05908526 · ClinicalTrials.gov registry record · Phase 2
Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT05908526 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 40 participants.
The verdict
NCT05908526, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The goal of this study is to examine the impact of suvorexant, an FDA-approved insomnia medication, on daytime symptoms (as measured by the Daytime Insomnia Symptoms Scale: cognition, positive mood, negative mood, and fatigue/sleepiness) among older adults with insomnia. The primary hypothesis is that relative to placebo, suvorexant will improve sleep and daytime symptoms. The word "placebo" refers to a harmless pill with no therapeutic effect.
Interventions
- OTHER Placebo
- DEVICE Actiwatch
- BEHAVIORAL Baseline surveys, Cognitive testing and EMAs
- DRUG suvorexant (or placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-10-09 |
| Est. Completion | 2024-08-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05908526
The ClinicalTrials.gov registry entry for NCT05908526 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05908526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05908526 about?
NCT05908526 is a clinical study titled "Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes". The goal of this study is to examine the impact of suvorexant, an FDA-approved insomnia medication, on daytime symptoms (as measured by the Daytime Insomnia Symptoms Scale: cognition, positive mood, negative mood, and fatigue/sleepiness) among older adults with insomnia. The primary hypothesis is th...
What is the current status of trial NCT05908526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-10-09. Estimated completion is 2024-08-08.
What interventions are being tested in trial NCT05908526?
The interventions under investigation include: Placebo (OTHER), Actiwatch (DEVICE), Baseline surveys, Cognitive testing and EMAs (BEHAVIORAL), suvorexant (or placebo) (DRUG).
Who is sponsoring clinical trial NCT05908526?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.